That said, Paclitaxel and Adriamycin have been shown to enhance AHR expression in MDA-MB-231 breast cancer cells [206] and AHR activity in cardiomyocytes [206], results that one would have expected would lead to a reduction in efficacy of a chemotherapeutic plus AHR inhibitor regimen. Here, AHR is linked to breast carcinoma.